Načítá se...
Predicting long‐term clinical stability in amyloid‐positive subjects by FDG‐PET
Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials. To test the predictive values in clinical progression of neuropathology change (amyloid‐PET) or brain metabolism as neurodegeneration biomarker ([18F]FDG‐PET), we evaluated data from N = 268 healthy c...
Uloženo v:
| Vydáno v: | Ann Clin Transl Neurol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6562030/ https://ncbi.nlm.nih.gov/pubmed/31211176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.782 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|